GlassScriptPhysician profile
Sarah J Nance
NPI 1841967288
$7,326.27
in general payments reported to CMS, 2019-2025
35 companies · $2,888 in 2025
The $2,888 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $109 · 2023: $1,767 · 2024: $2,563 · 2025: $2,888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,184 · Education: $33.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,184.26 |
| Education | $33.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,556.89 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $963.18 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $519.02 | 2023-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $479.17 | 2023-2025 | |
| Janssen Biotech, INC. | $338.44 | 2023-2025 | Stelara, Tremfya, Simponi |
| Aimmune Therapeutics, INC. | $322.57 | 2023-2025 | Zenpep, Vowst |
| Evoke Pharma, INC. | $292.99 | 2023-2025 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $255.54 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $237.87 | 2024-2025 | Voquezna |
| Medtronic, INC. | $206.92 | 2022-2025 | Interstim |
| Celltrion USA INC. | $190.65 | 2024-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $187.40 | 2023-2025 | Ibsrela |
| Pfizer INC. | $169.06 | 2023-2025 | |
| Madrigal Pharmaceuticals | $149.38 | 2025 | Rezdiffra |
| Qol Medical, LLC | $122.87 | 2023-2025 | Sucraid, Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $119.53 | 2024-2025 | Omvoh |
| Teva Pharmaceuticals USA, INC. | $118.71 | 2025 | Uzedy |
| Gilead Sciences, INC. | $106.94 | 2024-2025 | |
| Amgen INC. | $103.32 | 2025 | Evenity |
| Corium, LLC | $102.58 | 2023 | Azstarys |
| Regeneron Pharmaceuticals, INC. | $102.58 | 2023 | Dupixent |
| Neurelis, INC. | $92.47 | 2024 | Valtoco |
| Merck Sharp & Dohme LLC | $90.61 | 2023-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $88.50 | 2023 | Ocaliva |
| Celgene Corporation | $64.03 | 2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $64.00 | 2023-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $61.88 | 2025 | Rebyota |
| Novo Nordisk INC | $42.10 | 2025 | Wegovy |
| Sandoz INC. | $36.59 | 2023 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.04 | 2022-2023 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $30.91 | 2023 | |
| Lucid Diagnostics INC. | $20.95 | 2023 | |
| Axonics, INC. | $20.05 | 2024 | Axonics |
| Daiichi Sankyo INC. | $19.00 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $15.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Nance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.